about
Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infectionPopulation pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patientsSingle-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Ambulatory use of parenteral antibacterials: contemporary perspectives.Altered pharmacokinetics of ceftazidime in critically ill patients.Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infectionAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensWhat in vitro models of infection can and cannot do.Continuous infusion of nafcillin for sternal osteomyelitis in an infant after cardiac surgeryPopulation pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsComparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patientsKilling of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.High-level penicillin resistance and penicillin-gentamicin synergy in Enterococcus faecium.Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceApplication of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusionsPhase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.How I manage haematology patients with septic shock.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Improved outcomes of patients with end-stage cystic fibrosis requiring invasive mechanical ventilation for acute respiratory failure.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.
P2860
Q24675002-6E5BEDA1-5B6E-4ABE-B967-7C524AFE02FDQ33694347-4940F3E9-0C7C-42CF-B61B-C658BB7B00D9Q33697160-9E32B3F8-818C-4C13-BCC5-AFB6506D2DB0Q33722108-33E94A55-6FD9-443E-BB9A-E447130C2FE1Q33761118-A43E8D57-2967-4445-B224-BA3167501774Q33770046-D4B94260-3AAA-44D8-84D4-105D1CF7332CQ33938974-EDA7322C-D7D4-41D5-BD89-B2B51DF04C0CQ33977268-73C43A50-FFFA-4F39-882D-7374C72FB084Q33982991-6ACBDE36-C49F-42A0-9666-9D964BB5F9A4Q34111057-61F2AEB7-214B-4D6F-8B19-1FA6E0A8B8FEQ34141627-66C82C2E-FA84-44EB-801A-F7BAF09C279EQ34307105-5F796473-8830-4D9E-8A0B-5C0A070B249BQ34381321-D2BDB65E-F1E2-4D9F-831C-76B73D34F04EQ34443398-6498D50C-E309-4586-9D0D-9D2A463F1E4DQ34473155-81C43134-7C5B-4B46-9480-37B1C3F924D9Q34824085-F30892EE-E591-4ACD-B989-6F2AF07909D1Q35117352-36836274-94D5-4368-9593-956C328FEC98Q35121441-F8DB9961-E643-47DA-AF4F-306EE95948C7Q35123123-D95A8E88-FF7E-4D44-ADE2-85DAC37A28D4Q35123139-7ADD677E-4497-440F-818F-B5C69C6AD4E6Q35136125-44BE4EB5-7F6D-4B89-AB43-36E31A9B4F70Q35136449-F7C77B40-6815-46BB-9ED7-357A4F6B2DE1Q35138316-F4FC7974-128D-4188-8D87-90DBCB4AD802Q35820123-14329160-D961-4977-B348-264F24E106CBQ35900139-6D0FE7EF-57FF-4860-86B9-7A555AE2840AQ36094786-0EDA568B-7651-4349-88F7-55C66109E0BBQ36094911-5BCC0CCF-8D52-45EF-8131-46AE2F50C99CQ36329228-CCEE352A-CAB1-4C8D-9428-4DCE896A21A0Q36582692-29EC87A7-1E02-4373-962B-276ABE18CE51Q37115670-5A19F9C6-C498-44A1-BCCD-EE831C868DC9Q37190721-1F1A4F03-4F18-474D-8485-48927DC74603Q37247635-4BECF5B7-5F76-47D2-BD25-6CD49002B27DQ37287753-AC472D9D-5EB1-468B-BB21-635C442754E6Q37826436-9CC94A01-9C79-4C73-AD10-964485BFA9B0Q37838126-62593AA4-807F-4358-9512-40F18CE431DDQ37909115-25E2AD04-BDA4-4C81-B240-0613B5486831Q38896040-7EAC6FA4-FF25-44E5-9FFD-BFFEC96986BBQ39025281-C3F9A3AE-B1D6-4B9B-A08D-69A4150D61B9Q39778967-42F646CE-50DE-45AC-82B7-7A60910A602FQ39780375-5CC4E10A-D174-4A88-B0C1-01F86953F89B
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Continuous infusion of beta-lactam antibiotics
@ast
Continuous infusion of beta-lactam antibiotics
@en
type
label
Continuous infusion of beta-lactam antibiotics
@ast
Continuous infusion of beta-lactam antibiotics
@en
prefLabel
Continuous infusion of beta-lactam antibiotics
@ast
Continuous infusion of beta-lactam antibiotics
@en
P2860
P356
P1476
Continuous infusion of beta-lactam antibiotics
@en
P2093
P2860
P304
P356
10.1128/AAC.36.12.2577
P407
P577
1992-12-01T00:00:00Z